Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
Worldwide, an estimated 200,000 babies are born with Sickle Cell Anemia (SCA) annually.
1 Uganda site
3 to 9 Years
Sickle Cell Anaemia, SCA
Phase 3
Vaso-occlusive crisis in Sickle cell disease might alter myocardial function through micro vascular obstruction.
1 France site
> 18 Years
This clinical trial studies the effect of pre-transplant immunosuppression (PTIS) and donor stem cell transplant in treating patients with severe blood diseases (hemoglobinopathies).
1 United States site
2 to 30 Years
Early Phase 1
Sickle cell anemia (SCA) is one of the most neglected diseases worldwide, according to the World Health Organization.
1 Brazil site
18 to 60 Years
Not Applicable
The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult subjects with severe sickle cell disease (SCD).
5 United States sites
18 to 50 Years
Phase 1/Phase 2
This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.
1 United States site
8 to 21 Years
Hemoglobin SS
Phase 4
Pain is the primary complication of sickle cell disease (SCD), including vaso-occlusive crises and more persistent, chronic pain.
1 United States site
8 to 17 Years
HbSS, HbSC
Not Applicable
The long-term goal is to reduce stress and improve pain control with less opioid use in patients with sickle cell disease by promoting an intervention with self-management relaxation/distraction exercises, named You Cope, We Support (YCWS).
1 United States site
18 to 99 Years
HbSS, HbSC
Not Applicable
L-glutamine has been approved in the US to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients 5 years of age and older.
1 United States site
> 5 Years
HbSS, HbSC
Phase 4
Sickle cell disease is the most common single-gene disease in the world.
1 France site
20 to 40 Years
